In the current study, we have used corresponding immunoassays to investigate, if monitoring of aggrecan, or its fragments in the circulation, can be used as valid biomarkers for assessing joint-damage in RA patients, and moreover, characterized the fragments found in human serum. The gene discussed is ACAN; the disease is rheumatoid arthritis.